Business Context and Reporting Period
Company: AgeX Therapeutics, Inc. (Note: Request metadata referenced "Serina Therapeutics," but the filing is for AgeX Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date: July 21, 2023
Context: AgeX entered into a material definitive agreement to exchange $36 million of indebtedness owed to Juvenescence Limited for newly authorized Series A and Series B Preferred Stock. This transaction is intended to restore AgeX's stockholders' equity to at least $6 million to regain compliance with NYSE American listing requirements.
Key Financial Metrics
Debt Reduction: $36,000,000 (outstanding principal and accrued loan origination fees cancelled).
Equity Issuance: 211,600 shares of Series A Preferred Stock and 148,400 shares of Series B Preferred Stock.
Subscription Price: $100 per share of Preferred Stock (paid via debt cancellation).
Conversion Price: $0.72 per share of Common Stock (based on closing price prior to agreement).
Liquidity/Revenue: The filing text does not provide specific values for revenue, operating profit, cash flow, or current liquidity positions beyond the debt-for-equity swap.
Material Changes
- Capital Structure: Significant reduction in debt liabilities offset by the issuance of preferred equity.
- Listing Status: The transaction is a remedial measure to address non-compliance with NYSE American stockholders' equity requirements ($6 million threshold).
- Ownership Rights: Introduction of new preferred stock classes with specific liquidation preferences and voting rights on fundamental corporate changes.
Guidance, Outlook, and Risks
Outlook and Conditions:
- Consummation: Expected on or around July 25, 2023, subject to NYSE American approval of a supplemental listing application and filing of Certificates of Designation in Delaware.
- Automatic Conversion: Preferred Stock will automatically convert to common stock upon the earliest of: (1) consummation of a merger with Serina Therapeutics, Inc., or (2) February 1, 2024.
- Conversion Caps: Series B Preferred Stock conversion is subject to a 19.9% cap (7,550,302 shares) and a 50% cap on total ownership unless stockholder approval is obtained.
Risks and Contingencies:
- Listing Compliance: Continued listing remains dependent on a formal determination by the NYSE American that AgeX has regained compliance.
- Forward-Looking Statements: Actual results may differ materially due to factors outlined in the company's periodic reports under "Risk Factors."
- Registration Rights: AgeX agreed to register the common stock issuable upon conversion if Form S-3 is available, bearing registration expenses but not underwriting commissions.
Investor Verification Checklist
- Confirm whether the NYSE American has approved the supplemental application to list the common stock issuable upon conversion.
- Verify the filing of the Certificates of Designation for Series A and Series B Preferred Stock with the Delaware Secretary of State.
- Monitor the status of the proposed merger with Serina Therapeutics, Inc., which triggers automatic conversion of the Preferred Stock.
- Review the full text of the Exchange Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for detailed terms not summarized in the 8-K.
- Assess the impact of the 19.9% and 50% conversion caps on potential dilution and future capital raising capabilities.